|
Title
|
|
|
|
Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy : a randomized trial
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background: The blunting effect of pertussis immunization during pregnancy on infant antibody responses induced by whole-cell pertussis (wP) vaccination is not well-defined. Methods: This randomized controlled trial (NCT02408926) followed term infants born to mothers vaccinated with tetanus, diphtheria, and acellular pertussis (Tdap) vaccine during pregnancy in Thailand. Infants received either acellular pertussis (aP)- or wP-containing vaccine at 2, 4, 6, and 18 months of age. A comparison group comprised wP-vaccinated children born to mothers not vaccinated during pregnancy. Antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) were evaluated using commercial enzyme-linked immunosorbent assays. Functionality of antibodies against Bordetella pertussis was measured using Bordetella pertussis growth inhibition assay. Results: After maternal Tdap vaccination, 158 infants vaccinated with aP-containing vaccines possessed higher antibody levels (P < .001) against all tested B. pertussis antigens postpriming compared to 157 infants receiving wP-containing vaccines. At 1 month postbooster, only anti-FHA and anti-PRN antibodies were still significantly higher (P < .001) in the aP group. Significantly higher anti-PT and anti-FHA (P < .001), but not anti-PRN immunoglobulin G, were observed among 69 wP-vaccinated infants born to control mothers compared with wP-vaccinated infants of Tdap-vaccinated mothers after primary and booster vaccination. The antibody functionality was higher in all wP-vaccinated infants at all times. Conclusions: Maternal Tdap vaccination inhibited more pertussis-specific responses in wP-vaccinated infants compared to aP-vaccinated infants, and the control group of unvaccinated women had highest PT-specific responses, persisting until after the booster dose. Antibody functionality was better in the wP groups. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Clinical infectious diseases. - Chicago, Ill.
| |
|
Publication
|
|
|
|
Chicago, Ill.
:
2020
| |
|
ISSN
|
|
|
|
1058-4838
| |
|
DOI
|
|
|
|
10.1093/CID/CIZ778
| |
|
Volume/pages
|
|
|
|
71
:1
(2020)
, p. 72-80
| |
|
ISI
|
|
|
|
000551523900014
| |
|
Pubmed ID
|
|
|
|
31418814
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|